NCT01867866View on ClinicalTrials.gov

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

June 30, 2016

Conditions
Advanced Solid Tumors
Interventions
DRUG

TAS-102

35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

DRUG

Trifluridine

35 mg/m2, orally, single dose

Trial Locations (1)

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

All Listed Sponsors
lead

Taiho Oncology, Inc.

INDUSTRY

NCT01867866 - Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone | Biotech Hunter | Biotech Hunter